Overexpression of CRART16 increased the viability of gastric cancer cells after 5-day treatment with bevacizumab (0.5 mg/mL), suggesting that CRART16 promoted bevacizumab resistance (*P < 0.05; Figure 3A). This evidence concerns the gene LINC03145 and gastric cancer.